MET激酶结构域激活突变与其他驱动癌基因在NSCLC中共存并介导靶向治疗耐药
该研究对两个非小细胞肺癌(NSCLC)队列进行肿瘤基因组分析,发现MET酪氨酸激酶结构域(TKD)激活突变见于0.15%的病例,约半数与其他驱动癌基因共存;对8例连续基因组检测病例的回顾显示,88%的MET TKD突变在系统治疗后获得;体外模型证实该突变可介导靶向治疗耐药,联合针对原发癌基因和MET TKD突变的治疗可克服耐药。
要点
- MET TKD激活突变在NSCLC中占0.15%,约半数与其他驱动癌基因共存。
- 连续检测的8例中88%的MET TKD突变在系统治疗后获得。
- 体外联合抑制原发癌基因和MET TKD突变可克服耐药。
核心结论
- MET TKD突变可作为多种癌基因驱动的NSCLC的脱靶耐药机制。
- 联合有效的MET靶向治疗可能克服MET TKD突变介导的耐药。
研究设计与样本
- 对两个NSCLC患者队列进行肿瘤基因组分析,并对超过115,000例NSCLC患者进行基因组分析。
- 对8例具有连续基因组检测的病例进行回顾。
- 构建最常见MET TKD突变的临床前模型以检测对靶向治疗敏感性的影响,并探索克服耐药的策略。
主要发现
- MET TKD激活突变在0.15%的NSCLC病例中流行,约半数与其他驱动癌基因共存,共存模式随致癌改变不同而异。
- 8例连续基因组检测中88%的MET TKD突变在系统治疗后获得,APOBEC诱变可能参与此过程。
- 体外实验中,MET TKD突变在多种癌基因驱动模型中赋予靶向治疗耐药,联合针对原发癌基因和MET TKD突变的治疗可克服耐药。
临床怎么用
- 作者认为,联合有效的MET靶向治疗可能克服MET TKD突变介导的耐药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: MET tyrosine kinase domain (TKD) mutations have recently been characterized as de novo oncogenic drivers in NSCLC. Nevertheless, whether activating MET TKD mutations can confer resistance to targeted therapy in non-MET, oncogene-driven NSCLCs remains unclear. METHODS: To characterize the genomic features of tumors with MET TKD mutations in oncogene-driven NSCLC, we performed tumor genomic profiling on two different cohorts of patients with NSCLC. Preclinical models of the most frequently observed MET TKD mutations were generated to determine the effect on sensitivity to targeted therapy. Treatment strategies to overcome MET TKD mutation-mediated resistance were further explored. RESULTS: Genomic profiling of more than 115,000 patients with NSCLC found that activating MET TKD mutations are prevalent in 0.15% of cases, and that about half of them co-occur with another oncogenic driver, with a differential pattern in co-occurring MET TKD mutations according to the oncogenic alteration. A review of eight cases with sequential genomic testing revealed that the MET TKD mutation was acquired after systemic therapy in 88% of cases, with a potential contribution of APOBEC mutagenesis underlying this process. In vitro, MET TKD mutation conferred resistance to targeted therapy in diverse oncogene-driven models, which could be overcome by combinatorial treatment against both the primary oncogene and the MET TKD mutation. CONCLUSIONS: MET TKD mutation can act as an off-target resistance mechanism in diverse oncogene-driven NSCLC. Combination therapy with an effective MET-targeted therapy can potentially overcome MET TKD mutation-mediated resistance.
引用
- Nakazawa S, Pecci F, Ricciuti B, et al. Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC. J Thorac Oncol. 2025. PMID: 40185329. doi:10.1016/j.jtho.2025.03.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。